Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 1/20 | 0.49 |
| ▸ | CYP17A1 | P05093 | 4/20 | 0.45 |
| ▸ | PRMT5 | O14744 | 8/20 | 0.44 |
| ▸ | WDR77 | Q9BQA1 | 8/20 | 0.44 |
| ▸ | ATM | Q13315 | 1/20 | 0.44 |
| ▸ | CA12 | O43570 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
| ▸ | CA9 | Q16790 | 1/20 | 0.43 |
| ▸ | RORC | P51449 | 1/20 | 0.41 |
| ▸ | LCK | P06239 | 1/20 | 0.40 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14428036 | 0.90 | NAMPT (0.54) | NAMPTCYP17A1CA12CA1CA9 | |
| SCHEMBL29674394 | 0.84 | NAMPT (0.49) | NAMPTCYP17A1CA12CA1CA9 | |
| SCHEMBL12735928 | 0.84 | NAMPT (0.49) | NAMPTCYP17A1CA12CA1CA9 | |
| SCHEMBL12313962 | 0.83 | NAMPT (0.48) | NAMPTCYP17A1CA12CA1CA9 | |
| SCHEMBL8444197 | 0.83 | NAMPT (0.48) | NAMPTCYP17A1CA12CA1CA9 | |
| SCHEMBL13499908 | 0.83 | NAMPT (0.48) | NAMPTCYP17A1CA12CA1CA9 | |
| SCHEMBL29526828 | 0.83 | NAMPT (0.48) | NAMPTCYP17A1CA12CA1CA9 | |
| SCHEMBL14395618 | 0.83 | NAMPT (0.48) | NAMPTCYP17A1CA12CA1CA9 | |
| SCHEMBL1502539 | 0.83 | NAMPT (0.48) | NAMPTCYP17A1CA12CA1CA9 | |
| SCHEMBL30690810 | 0.83 | NAMPT (0.48) | NAMPTCYP17A1CA12CA1CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 102 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4568946-A1 | MACROCYCLIC BCL6 DEGRADERS | Dana-Farber Cancer Institute, Inc. (US) | 2025-06-18 | — | — | EP | disclosed |
| US-20250134869-A1 | Pyrrolo[2,3-d]pyrimidinyl, Pyrrolo[2,3-b]pyrazinyl and Pyrrolo[2,3-d]pyridinyl Acryla-mides | PFIZER INC (US) | 2025-05-01 | — | — | US | disclosed |
| CN-119585240-A | Macrocyclic BCL6 degrading agents | 丹娜-法伯癌症研究院 | 2025-03-07 | — | — | CN | disclosed |
| US-20250059157-A1 | TLR7/8 ANTAGONISTS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2025-02-20 | — | — | US | disclosed |
| US-12077533-B2 | Pyrrolo[2,3-d]pyrimidinyl, pyrrolo[2,3-b]pyrazinyl and pyrrolo[2,3-d]pyridinyl acrylamides | PFIZER INC. (US) | 2024-09-03 | — | — | US | disclosed |
| EP-3889145-B1 | 8-CYANO-5-PIPERIDINO-QUINOLINES AS TLR7/8 ANTAGONISTS AND THEIR USES FOR TREATING IMMUNE DISORDERS | MERCK PATENT GMBH (DE) | 2024-02-21 | — | — | EP | disclosed |
| WO-2024035688-A1 | MACROCYCLIC BCL6 DEGRADERS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2024-02-15 | — | — | WO | disclosed |
| US-20230303514-A1 | TLR7/8 ANTAGONISTS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2023-09-28 | — | — | US | disclosed |
| US-20230303514-A1 | TLR7/8 ANTAGONISTS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2023-09-28 | — | — | US | disclosed |
| US-11629134-B2 | TLR7/8 antagonists and uses thereof | MERCK PATENT GMBH (DE) | 2023-04-18 | — | — | US | disclosed |
| WO-2010026122-A1 | HETEROCYCLIC PIM-KINASE INHIBITORS | NOVARTIS AG (CH) | 2010-03-11 | — | — | WO | disclosed |
| WO-2009109576-A1 | PIM KINASE INHIBITORS AND METHODS OF THEIR USE | NOVARTIS AG (CH) | 2009-09-11 | — | — | WO | disclosed |
| WO-2009109576-A1 | PIM KINASE INHIBITORS AND METHODS OF THEIR USE | NOVARTIS AG (CH) | 2009-09-11 | — | — | WO | disclosed |
| US-7138530-B2 | Thiophene amidines, compositions thereof, and methods of treating complement-mediated diseases and conditions | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 2006-11-21 | — | — | US | disclosed |
| US-7109354-B2 | Thiophene amidines, compositions thereof, and methods of treating complement-mediated diseases and conditions | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 2006-09-19 | — | — | US | disclosed |
| EP-1549632-A4 | NOVEL THIOPHENE AMIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATING COMPLEMENT-MEDIATED DISEASES AND CONDITIONS | DIMENSIONAL PHARM INC (US) | 2005-11-09 | — | — | EP | disclosed |
| US-20050234081-A1 | Novel thiophene amidines, compositions thereof, and methods of treating complement-mediated diseases and conditions | SUBASINGHE NALIN | 2005-10-20 | — | — | US | disclosed |
| EP-1549632-A1 | NOVEL THIOPHENE AMIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATING COMPLEMENT-MEDIATED DISEASES AND CONDITIONS | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 2005-07-06 | — | — | EP | disclosed |
| US-20040009995-A1 | Novel thiophene amidines, compositions thereof, and methods of treating complement-mediated diseases and conditions | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2004-01-15 | — | — | US | disclosed |
| WO-2003099805-A1 | NOVEL THIOPHENE AMIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATING COMPLEMENT-MEDIATED DISEASES AND CONDITIONS | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 2003-12-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050234081-A1 | Novel thiophene amidines, compositions thereof, and methods of treating complement-mediated diseases and conditions | C5, C9, C1R | NAMPT 1948/4885CYP17A1 2979/4885PRMT5 952/4885 |
| US-20230303514-A1 | TLR7/8 ANTAGONISTS AND USES THEREOF | TLR7, TLR8, TLR9 | NAMPT 696/4885CYP17A1 2700/4885PRMT5 3297/4885 |
| US-20040009995-A1 | Novel thiophene amidines, compositions thereof, and methods of treating complement-mediated diseases and conditions | C5, C9, C1R | NAMPT 1833/4885CYP17A1 1958/4885PRMT5 1749/4885 |
| US-12077533-B2 | Pyrrolo[2,3-d]pyrimidinyl, pyrrolo[2,3-b]pyrazinyl and pyrrolo[2,3-d]pyridinyl acrylamides | ACR, PKD2, PGA5 | NAMPT 770/4885CYP17A1 816/4885PRMT5 1102/4885 |
| US-11629134-B2 | TLR7/8 antagonists and uses thereof | TLR7, TLR8, TLR9 | NAMPT 696/4885CYP17A1 2700/4885PRMT5 3297/4885 |
| US-20250134869-A1 | Pyrrolo[2,3-d]pyrimidinyl, Pyrrolo[2,3-b]pyrazinyl and Pyrrolo[2,3-d]pyridinyl Acryla-mides | JAK2, JAK3, JAK1 | NAMPT 2242/4885CYP17A1 4313/4885PRMT5 1044/4885 |
| US-20250059157-A1 | TLR7/8 ANTAGONISTS AND USES THEREOF | TLR7, TLR8, TLR9 | NAMPT 696/4885CYP17A1 2700/4885PRMT5 3297/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.